Targeting CXCR4/CXCL12 axis via [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub> with CXCR4 antagonist in triple-negative breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Guangfa,Bao

第一单位： Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China.

作者： Guangfa,Bao ^[1] ; Ziqiang,Wang ^[1] ; Luoxia,Liu ^[1] ; Buchuan,Zhang ^[1] ; Shuang,Song ^[1] ; Dongdong,Wang ^[1] ; Siyuan,Cheng ^[1] ; Eu-Song,Moon ^[2] ; Frank,Roesch ^[2] ; Jun,Zhao ^[3] ; Bo,Yu ^[1] ; Xiaohua,Zhu ^[4]

作者单位： Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China. ^[1] Department of Chemistry, Johannes Gutenberg University, 55131, Mainz, Germany. ^[2] Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China.;Department of Anatomy, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China.;Cell Architecture Research Center, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430030, China. ^[3] Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China. evazhu@vip.sina.com. ^[4]

关键词 CXCR4 antagonist CXCR4/CXCL12 Triple-negative breast cancer (TNBC)[177Lu]Lu-DOTAGA.(SA.FAPi)2